Seven Takeaways From “What’s Hot in Boston Biotech”
Sure, things may look great now, but it wasn’t long ago that Kendall Square was a biotech ghost town—and the good times might come to an end if we’re not careful. Meanwhile, gene therapy, cell therapy,...
View ArticleWhat’s Hot in Boston Biotech: The Photos
What’s Hot in Boston Biotech? Just about everything—but don’t mistake that for meaning the good times will roll on forever. As I wrote last week, that was one of the main themes of our latest biotech...
View ArticleDenali Rises With $217M and Genentech Alumni to Fight Brain Diseases
A group of investors is betting $217 million that a new drug company led by three Genentech alumni can break the frustrations of what, to now, has been a Sisyphean task: Finding treatments for the...
View ArticleFlagship CEO on Backing NY Biotech, Moderna, and Investing in a Boom
It’s been a jam-packed few months for Flagship Ventures, one of the Boston area’s most well-known biotech startup creators. The Cambridge, MA-based VC firm just raised a $537 million fund of its own,...
View ArticleEast Coast Biotech Roundup: Flagship, SQZ, Epizyme, IPOs & More
We’ve got a new site launch, local IPOs, and much more to dig through in this week’s roundup. But first, a programming note to you Xconomy readers: I’ll be away on a long break, returning in late...
View Article“Boston’s Life Science Disruptors” to Share Their Stories on Sept. 30
The concept of “disruption” has become a buzzword in biotech, a term signifying the dreams of companies looking to make a big impact on the world of healthcare. Yet that type of risk-taking and...
View ArticleVersant Walks Biotech “High Line” With a New Manhattan Incubator
Versant Ventures is about to launch its latest biotech incubator. And it’s picked the emerging New York life sciences scene as its home. This morning, Versant, the San Francisco Bay Area VC firm, is...
View ArticleHear the Synlogic Story at Boston’s Life Science Disruptors Sept. 30
Jose-Carlos Gutierrez Ramos had one of biopharma’s plum jobs as a top Pfizer executive. So why did he give it up to take the risk of running a biotech startup in, of all things, the uncertain field of...
View ArticleFive Takeaways From “Boston’s Life Science Disruptors”
The monsoon that drenched Boston before Xconomy’s biotech gathering on Wednesday was apropos; there’ve been storm clouds over the industry for a few weeks now. So much so that Flagship Ventures CEO...
View ArticleFlagship Pioneers New Name, $285M ‘Special Opportunities’ Fund
Flagship Ventures is changing its name and unveiling a new $285 million side fund that will pump more money into the firm’s portfolio companies when they are ready to rapidly grow. The follow-on fund...
View ArticleCheck Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today
Time is running out to get a discount on Xconomy’s annual Boston biotech bash, “What’s Hot in Boston Biotech.” We’re putting together a huge star-studded lineup of local biotech leaders to discuss...
View ArticleStifling Immigration Is “Retrograde”: Highlights From “What’s Hot”
View the Slideshow Drug pricing. The opioid epidemic. Boardroom diversity. Immigration crackdowns. The state of cancer care now, and in the future. These things aren’t just topics of conversation in...
View ArticleEvelo Bio Raises $50M Round to Bring Microbiome Drugs Into Trials
Bacteria have evolved with humans over many thousands of years, forming a delicate balance in the body that researchers are just now starting to understand. Evelo Biosciences believes it can tap into...
View ArticleDealmaker, Thought Leader & More: The X of the Year Xconomy Award Finalists
Given the size and diversity of the life sciences community in the Boston area, we at Xconomy knew that many candidates would be so unique that they wouldn’t fit neatly into a category. So we gave...
View ArticleAfter Humanitarian Honor, Flagship’s Afeyan States Case for Immigration
They embrace the unfamiliar, overcome adversity, and through it all, make the most of limited resources. These characteristics describe many entrepreneurs. But they also describe immigrants, says...
View ArticleBio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on...
View ArticleFlagship Bags $618M, Its Largest Raise Ever, For a New Startup Crop
More money continues to flow into the creation of new biotechs. Flagship Pioneering, one of the life science industry’s major early stage venture investors, announced today that it has raised $618...
View ArticleBoston Tech Watch: MIT Solves, AltioStar Raises & Enel Scouts
[Updated 5/9/19, 11:00 am. See below.] The week in Boston tech news saw the launch of a philanthropic venture fund at MIT, some large fundraising rounds, an open source acquisition, and more.—MIT is...
View ArticleFlagship Adds $1.1B for New Meds, More AI, &“Health Security”
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.One...
View ArticleBio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.ARCH Venture Partners led the pack, adding...
View Article
More Pages to Explore .....